feedback welcome

Doxepine-sertraline

From Psychiatrynet

(Difference between revisions)
Jump to:navigation, search
[checked revision][draft revision]
 
Line 3: Line 3:
| to = sertraline  
| to = sertraline  
| stop =  
| stop =  
-
* '''Before day 1:''' gradually reduce dosage of doxepin to a maximum of 100 mg/day.
+
{{stopDoxepin}}
-
* '''Day 1:''' reduce dosage of doxepin to 50 mg/day.
+
-
* '''Day 8:''' reduce dosage of doxepin to 25 mg/day.
+
-
* '''Day 15:''' stop administration of doxepin.
+
| start =  
| start =  
-
* '''Day 15:''' start administration of sertraline in a normal dosage of 50 mg/day.
+
* '''Day 16:''' start administration of sertraline in a normal dosage of 50 mg/day.
-
* '''Day 22:''' if necessary increase sertraline to 100 mg/day.
+
* '''Day 23:''' if necessary increase sertraline to 100 mg/day.
| info =  
| info =  
* {{theorSS}}
* {{theorSS}}
* Sertraline is a weak inhibitor of CYP2D6, which metabolizes doxepin.
* Sertraline is a weak inhibitor of CYP2D6, which metabolizes doxepin.
-
{{review}}  }}
+
}}

Current revision as of 12:35, 2 November 2015

Doxepin
Type antidepressant
Group TCA
links
ATC-code N06AA12
Medscape Doxepin
PubChem 3158
PubMed Doxepin
Drugs.com doxepin
Kompas (Dutch) Doxepin
Wikipedia Doxepin
Sertraline
Type Antidepressant
Group SSRI
links
Medscape Sertraline
PubChem 68617
PubMed Sertraline
Kompas (Dutch) Sertraline
Wikipedia Sertraline

Switch medication from doxepin to sertraline.

Nietinrijdenbord.png Stop doxepin
Eenrichtingbord.png Start sertraline
Infobord.png More information
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
Navigation
About